employer cover photo
employer logo
employer logo

Catalent Pharma

Is this your company?

Poor working conditions - Supervisor Catalent Pharma Employee Review

2.0
3 Aug 2021
Recommend
CEO approval
Business outlook

Pros

Fast paced environment; Cell and gene therapy field is evolving fast

Cons

Low manpower; numerous people leaving, and due to lack of resources , pressure is put on remaining ones. All activities cannot be done and project are delayed.

avatar
Catalent Pharma Response
4y
Thank you for taking the time to provide us with feedback on your experience with Catalent. I am sorry to hear about your experience. At Catalent we pride ourselves in continuous improvement for all areas of our business. Your feedback is what will help us to improve our employee experience at all levels.

Explore other reviews about Catalent Pharma

5.0
26 May 2026
Recommend
CEO approval
Business outlook

Pros

The team is incredibly welcoming, knowledgeable, and supportive, which has made it easy to learn and feel comfortable asking questions. There is a strong focus on training and collaboration, helping me feel safe, well prepared, and confident in my role. I also appreciate the benefits, which support a good work-life balance.

Cons

One area for improvement is the flexibility for new employees regarding remote work hours.

2.0
18 June 2026
Anonymous employee
Recommend
CEO approval
Business outlook

Pros

Adequate amount of PTO and suitable medical benefits and 401K. Co-workers were helpful and good resources when needed.

Cons

Difficult to receive promotions, as site GM, HR, and Global have to approve. No/very small annual increases. Departments need to hire additional support; again, difficult to get management and global to approve, thus a lot of turnover. Site directors/managers had conflicts between departments. Some would intentionally undermine other department heads if it suited their interest. Two directors have personal relationship, which seems to be conflict of interest.

2
See reviews by: Helpful|Rating|Date|All